United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products in the United States and internationally. The company is headquartered in Hauppauge, New York.
| Revenue (TTM) | $10.94M |
| Gross Profit (TTM) | $5.21M |
| EBITDA | $2.39M |
| Operating Margin | 22.40% |
| Return on Equity | 21.70% |
| Return on Assets | 11.20% |
| Revenue/Share (TTM) | $2.38 |
| Book Value | $2.37 |
| Price-to-Book | 3.46 |
| Price-to-Sales (TTM) | 3.08 |
| EV/Revenue | 2.71 |
| EV/EBITDA | 12.42 |
| Quarterly Earnings Growth (YoY) | 46.00% |
| Quarterly Revenue Growth (YoY) | 15.80% |
| Shares Outstanding | $4.59M |
| Float | $2.96M |
| % Insiders | 35.85% |
| % Institutions | 20.80% |
Volatility is currently expanding
HAUPPAUGE, N.Y., July 16, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today that the company's Board of Directors, at its meeting on July 14, 2026, declared a cash dividend of $0.30 per share, to be paid on August 4, 2026, to all stockholders of record as of the close of business on July 28, 2026.
United-Guardian's rally reflects stronger sales, distribution expansion and recovering cosmetic demand, but valuation and trade risks may limit its near-term appeal.
UG reports higher y/y earnings and sales in Q1, driven by strong demand for Renacidin and increased purchases of cosmetic ingredients.
United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript
HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UG and any ticker you trade — then tracks every position and per-strategy win rate.
